Eli Lilly (LLY): Company Profile and Investor Research Guide

The central investor question

Eli Lilly is best understood through one central investor question: Can Lilly convert extraordinary incretin demand into a durable multi-product metabolic franchise while manufacturing, competition, pricing and pipeline execution determine how much of today's growth becomes long-lived cash flow? Reported facts come from SEC filings. Operating interpretation asks what those numbers reveal about demand, pricing, mix and competitive position. Valuation judgment asks what future cash flows would justify the price an investor is being asked to pay.

Q2 2026 snapshot

Eli Lilly reported Q2 2026 revenue of $22.974 billion, up 48% year over year, with diluted EPS of $7.94. Growth was driven by Mounjaro and Zepbound volume. The company raised its 2026 full-year guidance to $85 to $87 billion.

Fast growth can be cyclical, acquisition-driven or dependent on an unusually favorable mix. Swoopr's approach is to use current results as the starting point for questions, not the finishing point for conclusions.

What Eli Lilly does

Lilly discovers, develops, manufactures and commercializes medicines across diabetes and obesity, oncology, immunology, neuroscience and other therapeutic areas. The current economics are unusually concentrated in tirzepatide-based Mounjaro and Zepbound, creating both exceptional growth and meaningful concentration risk.

Key metrics to track

• Mounjaro and Zepbound revenue
• Prescription and volume growth for incretin products
• Realized pricing versus gross-to-net adjustments
• Manufacturing capacity and supply availability
• R&D spending and pipeline advancement
• Oncology and immunology revenue diversification
• Competition from Novo Nordisk and pipeline entrants
• U.S. and international market share for GLP-1/GIP products

Business evolution

Lilly was founded in 1876 and built a broad pharmaceutical franchise over more than a century. The company's current chapter is defined by tirzepatide, a dual GLP-1/GIP receptor agonist that has achieved unusually rapid commercial success in diabetes and obesity. That success has transformed the company's revenue profile and raised the stakes for manufacturing execution, pipeline diversification and pricing sustainability.

Competitive advantages

Lilly's moat in tirzepatide is the manufacturing scale it has built, clinical evidence accumulated since launch, brand recognition among physicians and patients, and the breadth of indications being pursued. Novo Nordisk's semaglutide franchise is the primary competitor, with several other companies in development.

Reading the balance sheet alongside the income statement

The income statement should never be reviewed in isolation. Investors should reconcile net income to cash from operations, check that R&D spending is consistent with the pipeline's breadth and maturity, and verify that manufacturing investment is translating into supply. Stock-based compensation should be treated as an economic cost even when management excludes it from adjusted earnings.

Risks

Risks include pricing pressure from PBMs and government negotiation, competition from next-generation incretins, manufacturing failures or capacity shortfalls, pipeline setbacks in oncology and immunology, patent cliff exposure as tirzepatide exclusivity eventually ends, and regulatory changes to drug pricing in the United States.

Bull, base and bear cases

A bull case assumes tirzepatide remains the preferred incretin, additional indications are approved, manufacturing scales smoothly and the pipeline delivers multiple follow-on products. A base case assumes strong but normalizing incretin growth and modest pipeline contributions. A bear case assumes a competitor's GLP-1 erodes share, pricing comes under sustained political pressure, and pipeline setbacks increase concentration risk.

Valuation framework

Lilly requires scenario-based valuation. Investors should model tirzepatide revenue under different competitive and pricing assumptions, separately value the pipeline optionality, and test manufacturing scenarios that affect supply. Annualizing one quarter of peak growth would overstate the long-run earnings power.

Early warning signs

Watch for tirzepatide volume growth decelerating; gross-to-net adjustments widening; manufacturing supply constraints emerging; clinical trial failures in key pipeline programs; and competition gaining market share faster than consensus expects.

Filing review workflow

1. Read the earnings release and record the key performance indicators in a consistent spreadsheet.
2. Compare the current quarter against the four prior quarters and the same quarter of the prior year.
3. Reconcile reported GAAP income to operating cash flow and then to free cash flow.
4. Locate the adjusted or non-GAAP reconciliation table and understand each excluded item.
5. Read the risk factors and any new disclosures added since the previous filing.
6. Update a thesis ledger: list the assumptions you made when you first valued the company, and mark each as confirmed, challenged or changed.
7. Revisit the valuation model to ask whether the stock price still makes sense given what you now know.

Investor checklist

1. What does this company sell, to whom, under what pricing arrangement, and why do customers pay?
2. What is the primary source of competitive advantage, and what evidence supports that claim?
3. What is the trend in organic revenue growth excluding acquisitions and currency effects?
4. Is gross margin expanding or contracting, and what is driving the direction?
5. Is free cash flow growing in line with or faster than reported earnings?
6. What is the reinvestment rate, and is capital allocation creating or destroying value?
7. How much debt is on the balance sheet, what are the covenants, and can the company service it through a downturn?
8. What is the base-case scenario, and what assumptions does it require about the competitive environment?
9. What would cause the bear case to materialise, and how quickly would you identify it?
10. At what price does the stock become clearly cheap under the bear case, and at what price does it require the bull case to justify it?

Common misconceptions

1. Strong revenue growth means a stock is a good investment. Growth creates value only when the return on incremental capital exceeds the cost of that capital.
2. High EBITDA is the same as cash profit. EBITDA excludes maintenance capital expenditure and can differ materially from free cash flow.
3. Share buybacks always benefit shareholders. Buybacks are only accretive when the shares are purchased below intrinsic value; buybacks funded by debt at elevated valuations can destroy value.
4. A great company is a great stock at any price. Even high-quality businesses can be overvalued, and a high entry price reduces the margin of safety.
5. Index membership signals quality or investment merit. Inclusion is mechanical, driven by rules about size and tradability, not by any assessment of valuation or competitive strength.

Frequently asked questions

References

• SEC EDGAR: Eli Lilly and Company filings
• Eli Lilly: Investor Relations